New and Emerging Therapies for Agitation Associated with Dementia Due to Alzheimer’s Disease (AD) An Interactive Learning Experience
Agitation is among the most common behavioral symptoms in patients with dementia, including Alzheimer’s dementia. It exacts a significant burden on patients because it is associated with not only greater morbidity and mortality, but also a faster cognitive and functional decline. This activity reviews pharmacological treatment options, both a newly approved agent that is the first ever to be indicated specifically for the treatment of agitation associated with dementia due to Alzheimer’s disease and also an array of agents in development.
- Review efficacy and safety data for the first therapy approved for agitation associated with dementia due to Alzheimer’s disease
- Discuss the mechanism of action and available efficacy and safety data for emerging therapies for agitation associated with dementia due to Alzheimer’s disease
Pierre N. Tariot, MD
Banner Alzheimer’s Institute
Alzheimer’s Prevention Initiative
Research Professor of Psychiatry
University of Arizona College of Medicine
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Pierre N. Tariot, MD: Advisor for AC Immune, Acadia, Athira, Corium Cortexyme, Eisai, Genentech, Merck, Novo Nordisk, Otsuka Lundbeck; Consultant for Abbvie, Acadia, Otsuka & Astex, T3D Therapeutics; Researcher for Abbvie, Biogen, Cortexyme, Eli Lilly, Genentech, Merck, NIA, Novartis, Roche; Royalties or Patent Beneficiaries for U.S. Patent # 11/632,747.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This activity is approved for 0.36 contact hours of continuing education, which includes 0.36 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 0.36 AANP Contact Hours
- 0.36 AANP Pharmacology Contact Hours
- 0.50 AMA PRA Category 1 Credit™
This course is offered through Pri-Med.
To take this course you will be redirected to Pri-Med's website. You must login or create an account with Pri-Med in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch